357 related articles for article (PubMed ID: 26087904)
1. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
Reuss DE; Kratz A; Sahm F; Capper D; Schrimpf D; Koelsche C; Hovestadt V; Bewerunge-Hudler M; Jones DT; Schittenhelm J; Mittelbronn M; Rushing E; Simon M; Westphal M; Unterberg A; Platten M; Paulus W; Reifenberger G; Tonn JC; Aldape K; Pfister SM; Korshunov A; Weller M; Herold-Mende C; Wick W; Brandner S; von Deimling A
Acta Neuropathol; 2015 Sep; 130(3):407-17. PubMed ID: 26087904
[TBL] [Abstract][Full Text] [Related]
2. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
Stichel D; Ebrahimi A; Reuss D; Schrimpf D; Ono T; Shirahata M; Reifenberger G; Weller M; Hänggi D; Wick W; Herold-Mende C; Westphal M; Brandner S; Pfister SM; Capper D; Sahm F; von Deimling A
Acta Neuropathol; 2018 Nov; 136(5):793-803. PubMed ID: 30187121
[TBL] [Abstract][Full Text] [Related]
3. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
[TBL] [Abstract][Full Text] [Related]
4. Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
Teske N; Karschnia P; Weller J; Siller S; Dorostkar MM; Herms J; von Baumgarten L; Tonn JC; Thon N
J Neurooncol; 2022 Jan; 156(2):317-327. PubMed ID: 34902093
[TBL] [Abstract][Full Text] [Related]
5. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
[TBL] [Abstract][Full Text] [Related]
6. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
7. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
[TBL] [Abstract][Full Text] [Related]
8. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
Reuss DE; Mamatjan Y; Schrimpf D; Capper D; Hovestadt V; Kratz A; Sahm F; Koelsche C; Korshunov A; Olar A; Hartmann C; Reijneveld JC; Wesseling P; Unterberg A; Platten M; Wick W; Herold-Mende C; Aldape K; von Deimling A
Acta Neuropathol; 2015 Jun; 129(6):867-73. PubMed ID: 25962792
[TBL] [Abstract][Full Text] [Related]
9. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of molecular analysis in diffuse glioma stratification.
Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
[TBL] [Abstract][Full Text] [Related]
11. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status.
Hyare H; Rice L; Thust S; Nachev P; Jha A; Milic M; Brandner S; Rees J
Eur J Radiol; 2019 May; 114():120-127. PubMed ID: 31005161
[TBL] [Abstract][Full Text] [Related]
12. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
[TBL] [Abstract][Full Text] [Related]
13. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
14. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.
Wiestler B; Claus R; Hartlieb SA; Schliesser MG; Weiss EK; Hielscher T; Platten M; Dittmann LM; Meisner C; Felsberg J; Happold C; Simon M; Nikkhah G; Papsdorf K; Steinbach JP; Sabel M; Grimm C; Weichenhan D; Tews B; Reifenberger G; Capper D; Müller W; Plass C; Weller M; Wick W;
Neuro Oncol; 2013 Aug; 15(8):1017-26. PubMed ID: 23595628
[TBL] [Abstract][Full Text] [Related]
15. Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series.
Kibe Y; Motomura K; Ohka F; Aoki K; Shimizu H; Yamaguchi J; Nishikawa T; Saito R
Sci Rep; 2023 Jan; 13(1):23. PubMed ID: 36646712
[TBL] [Abstract][Full Text] [Related]
16. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
17. Copy Number Profiling of Brazilian Astrocytomas.
Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM
G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220
[TBL] [Abstract][Full Text] [Related]
18. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
19. Comparative transcriptomics reveals similarities and differences between astrocytoma grades.
Seifert M; Garbe M; Friedrich B; Mittelbronn M; Klink B
BMC Cancer; 2015 Dec; 15():952. PubMed ID: 26673168
[TBL] [Abstract][Full Text] [Related]
20. Molecular landscape of IDH-wild-type, H3-wild-type glioblastomas of adolescents and young adults.
Shi ZF; Li KK; Huang QJ; Wang WW; Kwan JS; Chen H; Liu XZ; Li WC; Chan DT; Zhang ZY; Mao Y; Ng HK
Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12802. PubMed ID: 35191072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
